BioPharmSignal logoBioPharmSignal

Biotech News

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

Ibio Inc (IBIO)Ibio IncClinical readout

IBIO (IBIO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ibio.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

RXRXRecursion2025-12-01 13:30 EST

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

AZNAstraZeneca PLC2016-08-09 06:00 EST

ASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL

AZNAstraZeneca PLC2016-10-26 06:00 EST

Positive results in AstraZeneca Lynparza trial

IBIOIbio Inc2026-05-08 11:15 EST

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

View all latest news

Ibio Inc

iBio is a biotechnology company focused on next-generation biologics discovery and development platforms. Its story centers on trying to build value from engineering tools that can support therapeutic discovery and drug design.

Recent company news

IBIOIbio Inc2026-07-01 11:00 EST

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

IBIOIbio Inc2026-06-02 20:01 EST

iBio to Participate in Upcoming Healthcare Investor Conferences

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

IBIOIbio Inc2026-05-12 20:05 EST

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

IBIOIbio Inc2026-05-08 11:15 EST

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

Stock data

Close
1.45 USD
Market cap
87.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States